Chinese Version
English Version
On August 4, 2026, Frost & Sullivan, together with TradeGo, LeadLeo Research Institute, and China Credit Green Gold, officially released the Chinese version of '2026 Hong Kong Stock 18A Biotech Industry Development Blue Book' at the 20th Frost & Sullivan Global Growth, Innovation and Leadership Summit and the 5th New Investment Conference. This document systematically outlines the Hong Kong Stock 18A biotech industry ecosystem, capital market cycle evolution, innovation progress in various technology sectors, industrial chain development, and global development landscape, providing reference for industry professionals, investment institutions, and researchers.
Photo of the release of the Chinese version of the Hong Kong Stock 18A Blue Book
In September, the English version of the blue book ('The 2026 Blue Book on the Development of Hong Kong Stock Exchange 18A Biotech Sector') was launched on Frost & Sullivan's global website and distributed through multiple channels worldwide. Over 10 international key media were involved in this global distribution effort, forming a communication network including top global news agencies such as The Associated Press, as well as leading North American financial media like Yahoo Finance, Business Insider, and Dow Jones Market Watch. Additionally, the distribution network extended to countries and regions such as Germany, France, the UK, Italy, South Korea, Japan, and the UAE, integrating authoritative local industry media, financial portals, and mainstream news organizations. The total number of cooperative media exceeded 500, with more than 900 news releases published globally.
Website image
Publication status on some overseas websites
Thanks to Frost & Sullivan's professional industry analysis, this global distribution helped antibody companies establish international brand images, efficiently advance their international strategic layout, and further promote exchanges and cooperation among global and Chinese biotech companies, creating favorable conditions for Chinese biotech companies to deeply integrate into the global innovation ecosystem.
Scan with WeChat to obtain the report
Chinese Version
English Version
01
The capital market has gone through cycles, and investment logic has shifted towards fundamental value.
Since the implementation of the Hong Kong Stock Exchange 18A listing rules, Hong Kong has become the core financing hub for unprofitable biotech companies in Greater China. The global biotech capital market experienced an upward boom, a historical high in 2021, and a deep correction from 2022 to 2023, entering a recovery phase from 2024 to 2026.
The Hong Kong Stock 18A sector experienced a significant decline in 2021-2022, with market value significantly shrinking; in 2023, valuation reached a bottom. Driven by both inflows of southbound funds and a surge in domestic innovative drug international sales, the sector began a strong recovery from mid-2024. Market mentality has evolved, completely abandoning concept speculation, with investment focus shifting back to clinical milestones achievement, commercialization, real sales, and sustainable profitability. The capital market's pricing logic has shifted from story expectations to corporate fundamentals.
The report compares the trends of Hengsheng Basic Science, CSI Biotech, NASDAQ Biotech, and S&P Biotech indices horizontally, and also provides a comprehensive analysis of all data related to 18A companies' IPO offerings, primary market financing, and secondary market performance after listing.
02
Innovative pipelines are flourishing, and cutting-edge technologies are reshaping the research and development paradigm.
Hong Kong Stock 18A listed companies cover all sectors of medical devices, including small molecule drugs, antibodies, vaccines, nucleic acid drugs, CGT cell gene therapy, peptides, as well as IVD diagnostic devices, surgical robots, and endoscopes. Traditional monoclonal antibodies and small molecule drugs remain the core of the industry; cutting-edge sectors such as bispecific antibodies, ADCs, nucleic acids, CGT, and GLP-1 peptides are rapidly growing, with pipelines continuously expanding, and industry growth is shifting from pipeline quantity expansion to product structural upgrading.
AI and synthetic biology are redefining the entire drug development process. AI is deeply involved in target discovery, protein/antibody molecule design, molecular generation optimization, and clinical trial design, shortening the development cycle and improving clinical success rates; synthetic biology provides a new path for the engineering development of next-generation biologics, gradually becoming a core competitive advantage for companies.
03
The globalization process is accelerating, and the sector is experiencing three major structural changes.
Cross-border BD transactions in China's biopharmaceutical industry continue to be hot, with the scale of license-out transactions rising, and new cooperation models emerging. Assets licensed out are shifting from small molecules to cutting-edge innovations such as ADCs, bispecific antibodies, and nucleic acids; domestic companies are promoting global multi-regional clinical trials and overseas regulatory submissions, gradually building global commercialization capabilities. Hong Kong has evolved from a simple listing financing channel to a global platform for discovering and integrating global value of innovative assets.
The sector has experienced three fundamental structural changes:
1. Institutional positioning change: From a simple financing channel, it has become a global innovation resource connector;
2. Evaluation system change: Market evaluation criteria have shifted from pipeline quantity to clinical value, global execution ability, and commercialization achievement;
3. Business operation change: Companies have shifted from IPO financing orientation to building long-term operational capabilities and global competitiveness.
At the same time, the report systematically analyzes the current ESG disclosure status, existing challenges, and optimization directions of Hong Kong Stock 18A biotech companies, covering disclosure rates, ratings, and practices in various ESG dimensions.
04
Future outlook for the industry, with a new stage of enterprise capability differentiation beginning.
Looking ahead, the differentiation in the Hong Kong Stock 18A sector will intensify further. Companies will compete not only on pipeline layout but also on commercialization capabilities, global development abilities, and underlying original technical barriers. The capital market will continue to adopt long-term value pricing; cross-border BD and global clinical layouts will become the regular choices of leading companies; AI and synthetic biology will continue to evolve, driving pipeline innovation; ESG will also gradually become an important component of biotech company operations.
